Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors

International Journal of Dermatology

Volumn 49, Issue 1, 2010, Pages 91-94

  Habib, Nancy ^a   Salaro, Cristina ^b   Al Ghaithi, Khalid ^b   Phelps, Robert G ^b   Saggar, Sarika ^a   Cohen, Steven R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADVERSE OUTCOME; APHTHOUS STOMATITIS; APHTHOUS ULCER; ARTICLE; BIOPSY; BUDD CHIARI SYNDROME; CASE REPORT; CHILD; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIP; MALE; NEUTROPHIL CHEMOTAXIS; TONGUE; TONGUE BIOPSY;

ADMINISTRATION, ORAL; BUDD-CHIARI SYNDROME; CALCINEURIN; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROTEIN-SERINE-THREONINE KINASES; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STOMATITIS, APHTHOUS; TONGUE DISEASES;

EID: 73149087877     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04319.x     Document Type: Article

References (12)

1. Femiano F, Lanza A, Buonaiuto C. Guidelines for diagnosis and management of aphthous stomatitis. Pediatr Infect Dis J 2007, 26:728-732.
2. Macario-Barrel A, Tanasescu S, Courville P. Mouth ulcers in patients receiving tacrolimus. Ann Dermatol Venereol 2001, 128:1327-1329.
3. Mahe E, Morelon E, Lechaton S. Cutaneous adverse effects in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005, 79:476-482.
4. Hernandez G, Jimenez C, Arriba L. Resolution of oral ulcerations after decreasing the dosage of tacrolimus in a liver transplantation recipient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001, 92:526-531.
5. Montalbano M, Neff GW, Yamashiki N. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004, 78:264-268.
6. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005, 56:23-46.
7. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002, 12:618-622.
8. Casas-Melley AT, Falkenstein KP, Flynn LM. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004, 8:362-366.
9. Webster AC, Woodroffe RC, Taylor RS. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005, 331:810.
10. Schaffellner S, Jakoby E, Kniepeiss D. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005, 5:137-140.
11. van GelderT, ter MeulenCG, Hene R. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003, 75:788-791.
12. Reitamo S, Spuls P, Sassolas B. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001, 145:438-445.